It could be argued that GLP-1s hold therapeutic potential for certain eating disorder subtypes, particularly binge eating disorder and bulimia nervosa
Event Phase 2 Rate (12 mg group) Phase 2 Rate (Placebo) Nausea 45.8% 11.6% Diarrhea 33.3% 9.3% Vomiting 22.2% 2.3% Constipation 16.7% 7.0% Decreased appetite 22.2% 2.3% The nausea incidence at the highest dose a nausea percentage of roughly 46% makes it the single most reported adverse event in retatrutide clinical trials 2026 data
Konservierungsstoffe: Kaliumsorbat, Natriumbenzoat
Olivia de Rougemont is GP Lead at MedExpress, with over 14 years experience across the NHS and private sectors
Simple, once-weekly injections Reduces cravings and hunger Supports gradual, healthy weight loss Prescription delivered to your door Personalized care coaching support Proven results in clinical trials Frequently asked questions Weve tried to answer some of the most common questions about semaglutide here
Then counterstained with eosin for 1 min